Alpha Teknova, Inc. (TKNO)
| Market Cap | 173.39M |
| Revenue (ttm) | 40.52M |
| Net Income (ttm) | -17.26M |
| Shares Out | 53.61M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,706 |
| Open | 3.120 |
| Previous Close | 3.140 |
| Day's Range | 3.070 - 3.250 |
| 52-Week Range | 1.910 - 7.480 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About TKNO
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and dr... [Read more]
Financial Performance
In 2025, Alpha Teknova's revenue was $40.52 million, an increase of 7.35% compared to the previous year's $37.75 million. Losses were -$17.26 million, -35.47% less than in 2024.
Financial StatementsNews
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of n...
Alpha Teknova Transcript: Sidoti March Small-Cap Virtual Conference
Revenue reached $40.5 million in 2025 with strong growth in both catalog and custom GMP products. Investments in sales, marketing, and technology, along with a new GMP facility, position the business for profitability by 2027. Clinical Solutions and Lab Essentials segments drive future upside as therapies advance through clinical stages.
Alpha Teknova Earnings Call Transcript: Q4 2025
Revenue grew 7% in 2025 with improved gross margins and reduced losses. Investments in commercial capabilities and a recovering biotech market are expected to drive future growth, with positive adjusted EBITDA targeted by end of 2027.
Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provi...
Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova Earnings Call Transcript: Q3 2025
Q3 2025 saw 9% revenue growth and improved gross margins, led by strong Lab Essentials sales, while Clinical Solutions revenue declined. The outlook remains cautious for biopharma custom products, but double-digit growth continues in other segments. Guidance for 2025 revenue is $39–$42 million, with no need for additional capital.
Teknova Reports Third Quarter 2025 Financial Results
Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million
Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025
HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova Earnings Call Transcript: Q2 2025
Q2 2025 saw 7% revenue growth, strong catalog sales, and improved gross margin to 38.7%. Clinical Solutions revenue rose 32% YoY, while guidance for 2025 was reiterated at $39–$42 million. Operational efficiencies and a growing customer base support long-term growth.
Teknova Reports Second Quarter 2025 Financial Results
Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million...
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova Transcript: Sidoti May Micro-Cap Virtual Conference
Custom and catalog reagent provider leverages recent infrastructure investments to scale rapidly, targeting 20%-25% growth and higher margins. Strong customer retention, fast turnaround, and new partnerships position the business for long-term profitability and expansion.
Alpha Teknova Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 5% year-over-year to $9.8M, with strong catalog product growth and improved gross margin. Guidance for 2025 was reiterated, expecting 7% revenue growth and continued margin improvement, while a new collaboration with Pluristyx expands the product portfolio.
Teknova Reports First Quarter 2025 Financial Results
First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2...
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of n...
Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies
HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is avai...
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies
Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel...
Alpha Teknova Earnings Call Transcript: Q4 2024
2024 saw revenue growth, improved cash flow, and reduced expenses, with strong gains in clinical and biopharma segments. 2025 guidance anticipates 7% revenue growth, margin expansion, and continued cost discipline amid cautious customer spending and macro uncertainty.
Teknova Reports Fourth Quarter and Full Year 2024 Financial Results
Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provi...
Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova Transcript: Stephens 26th Annual Investment Conference | NASH2024
The company has stabilized after a challenging period, with strong growth in its catalog business and expanding clinical customer base. New offerings like Express-Tek and RUO+ are gaining traction, and cost reductions have positioned the business for profitability. Long-term growth targets remain ambitious, with a focus on innovation and operational efficiency.
Alpha Teknova Earnings Call Transcript: Q3 2024
Q3 2024 saw 17% revenue growth year-over-year, driven by biopharma custom product sales and increased clinical customer count. Gross margin was impacted by a $2.8M inventory write-down, but cost controls led to the lowest free cash outflow in three years. 2024 revenue guidance is flat, with liquidity sufficient to reach profitability.
Teknova Reports Third Quarter 2024 Financial Results
Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior year Company lowers 2024 total free cash outflow outlook to less than $16 million Company reaffirms 2024 revenue g...
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova Transcript: Sidoti Micro-Cap Virtual Conference
A custom reagents provider is leveraging a new GMP-certified facility, proprietary product launches, and a focused commercial strategy to drive growth, especially in cell and gene therapy. Financial targets include breakeven at $50–$55M revenue, with recent funding expected to support the path to profitability.